TrialAmerican journal of clinical dermatology2025

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Kim A Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.